Two new drugs for rheumatoid arthritis

    loading  Checking for direct PDF access through Ovid

Abstract

Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease that causes inflammation and destruction of the joints.1-3 It can also affect the eyes, the heart and the lungs and is associated with significant disability and increased mortality. RA is estimated to affect just under 1% of the population aged over 16 years, equating to more than 400,000 people in the UK.4 [Black Down-Pointing Triangle]Baricitinib (Olumiant) and [Black Down-Pointing Triangle]tofacitinib (Xeljanz) were launched in the UK in April 2017 and represent a new therapeutic class of medicines known as targeted synthetic disease modifying antirheumatic drugs.5,6 Here, we review the evidence for the safety and effectiveness of these new oral agents.

Related Topics

    loading  Loading Related Articles